China The latest news from Chinese pharma, including a new report showing that despite the increasing number of Priority Review and Breakthrough Therapy designations awarded within China, only two Accelerated Approval designations have been awarded since 2015. Elsewhere, Pfizer is utilising drone technology to promote health education in remote areas and…
China The latest from Chinese pharma, including a new deal between AstraZeneca and Junshi Biosciences; Innoforce and dMed’s R&D collab; and investment news on Clover Biopharmaceuticals, Sciwind Biosciences, and Gensciences. AstraZeneca signs deal with Chinese biotech Junshi Biosciences to market anti-PD-1 cancer drug in China https://www.biopharma-reporter.com/Article/2021/03/01/AstraZeneca-betting-on-China-s-PD-1-cancer-market AstraZeneca has signed a…
China A selection of recent big stories from Chinese pharma, including Novo Nordisk’s updated China strategy, Chinese biotechs’ funding successes, and some significant regulatory approvals. In Q1 2020, China’s regulator the National Medical Products Administration (NMPA) approved a total of 11 new drugs, 6 imported and 5 domestic Made with Visme…
Coronavirus Chinese biotech Clover Biopharmaceuticals may have flown under the radar thus far but it has stepped into the global limelight recently by partnering with GSK to develop a vaccine from the novel coronavirus, COVID-19, now wreaking havoc around the world. But who exactly are the brains behind Clover Biopharmaceuticals and…
Spain José Luis Martin, director general of HC Clover, a Spanish manufacturer of soft gelatin capsules, highlights how they adapt their services to clients as well as their strategy for rapid growth, such as the recent expansion of operations into Brazil. Furthermore, he touches on the competitive nature of the market…
See our Cookie Privacy Policy Here